首页> 外文OA文献 >Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study” and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid

【2h】

Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study” and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid

机译：评论“除了二肽基肽酶-4抑制剂以外的口腔糖尿病药物与大疱性毒性的情况无关：芬兰国家病例对照研究”和胰高血糖素肽-1受体激动剂诱导的大疱性大疱性Pemphigoid的病例报告

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Zachary Schwager; Anar Mikailov; Adam D. Lipworth;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid'' [J] . Varpuluoma Outi, Tasanen Kaisa, Huilaja Laura Journal of the American Academy of Dermatology . 2019,第6期

机译：回复：“评论除了二肽基肽酶-4抑制剂以外的口腔糖尿病药物与大疱性毒性的抑制剂无关：芬兰国家病例对照研究'以及胰高血糖素肽-1受体激动剂诱导的大疱病 '
2. Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study'' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid [J] . Schwager Zachary, Mikailov Anar, Lipworth Adam D. Journal of the American Academy of Dermatology . 2019,第6期

机译：评论“除了二肽基肽酶-4抑制剂以外的口腔糖尿病药物与大疱性疱疹病毒（Dellous Pemphigoid）无关：芬兰国家病例对照研究”“和胰高血糖素肽-1受体激动剂诱导的大疱病毒诱导的大疱病
3. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study [J] . Gy?rgy Jermendy, Zoltán Kiss, Gy?rgy Rokszin, Diabetes therapy . 2018,第5期

机译：在2型糖尿病患者中持续使用新型抗糖尿病药物（二肽基肽酶4抑制剂，钠葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂）进行的全国性队列研究
4. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study [O] . György Jermendy, Zoltán Kiss, György Rokszin, 2018

机译：在2型糖尿病患者中持续使用新型抗糖尿病药物（二肽基肽酶4抑制剂钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂）进行的全国性队列研究
5. Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study” [O] . Khalaf Kridin 2018

机译：评论“除了二肽肽酶-4型抑制剂以外的口腔糖尿病药物与大疱性斑肽无关：芬兰国家案例控制研究”

Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study” and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid

著录项

相似文献

相关主题

期刊订阅